{"id":533345,"date":"2021-03-09T11:56:01","date_gmt":"2021-03-09T11:56:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=533345"},"modified":"2021-03-09T11:56:01","modified_gmt":"2021-03-09T11:56:01","slug":"acute-respiratory-distress-syndrome-ards-market-size-and-share-epidemiology-and-competitive-analysis-report-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/acute-respiratory-distress-syndrome-ards-market-size-and-share-epidemiology-and-competitive-analysis-report-by-delveinsight_533345.html","title":{"rendered":"Acute Respiratory Distress Syndrome (ARDS) Market Size and Share, Epidemiology and Competitive Analysis Report by DelveInsight"},"content":{"rendered":"
\"Acute<\/a><\/p>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight\u2019s \u2018Acute Respiratory Distress Syndrome (ARDS) – Market Insights, Epidemiology and Market Forecast – 2030\u2019 report delivers an in-depth understanding of the Acute Respiratory Distress Syndrome (ARDS), historical and forecasted epidemiology as well as the Acute Respiratory Distress Syndrome (ARDS) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n

DelveInsight launched a new report on Acute Respiratory Distress Syndrome Market Insights, Epidemiology and Market Forecast 2030<\/strong><\/a>.<\/p>\n

Acute respiratory distress syndrome (ARDS) is a rapidly progressive disease occurring in critically ill patients. The main complication in ARDS is that fluid leaks into the lungs, making breathing difficult or impossible. Acute lung injury (ALI) is a common condition characterized by acute severe hypoxia that is not due to left atrial hypertension. <\/p>\n

DelveInsight’s ‘Acute Respiratory Distress Syndrome (ARDS) Market Report 2030<\/strong><\/a>’ delivers an in-depth understanding of the Acute Respiratory Distress Syndrome (ARDS), historical and forecasted epidemiology as well as the Acute Respiratory Distress Syndrome (ARDS) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

\"\"<\/p>\n

The term ALI encompasses a continuum of clinical and radiographic changes that affect the lungs with the acute respiratory distress syndrome (ARDS) representing the more severe end of this continuum. Despite advances in the understanding of the pathophysiology and management of ALI, it is still associated with high mortality.<\/p>\n

“In the 7MM, the total incident population of ARDS is estimated to be 7,99,872 <\/span>in 2017.”<\/p>\n

Acute Respiratory Distress Syndrome Emerging Drug Therapies:<\/strong><\/p>\n

1. Traumakine: Faron Pharmaceuticals<\/em><\/span><\/p>\n

2. BIO-11006: BioMarck Pharmaceuticals<\/p>\n

3. MultiStem: Athersys<\/p>\n

4. Solnatide: Apeptico Forschung und Entwicklung GmbH<\/p>\n

“The market size of Acute Respiratory Distress Syndrome (ARDS) in the seven major markets is USD 3,007.1 Million in 2017.”<\/strong><\/p>\n

Table of contents:<\/strong>
1 Key Insight
2 Executive Summary of ARDS
3 Acute Respiratory Distress Syndrome (ARDS) Market Overview at a Glance
4 Disease Background and Overview: ARDS
5 Case Reports
6 Acute Respiratory Distress Syndrome (ARDS)Epidemiology and Patient Population
7 United States Epidemiology
8 EU5 Epidemiology
9 Japan Epidemiology
10 Current Acute Respiratory Distress Syndrome (ARDS) Treatment and Medical Practices
11 Unmet needs
12 Acute Respiratory Distress Syndrome (ARDS) Marketed Drugs
13 Acute Respiratory Distress Syndrome (ARDS) Emerging Drugs
14 Acute Respiratory Distress Syndrome (ARDS) 7MM Market Analysis
15 United States
16 EU-5 countries: Market Outlook
17 Japan Market Outlook
18 Acute Respiratory Distress Syndrome (ARDS) Market Drivers
19 Acute Respiratory Distress Syndrome (ARDS) Market Barriers
20 SWOT Analysis
21 Reimbursement and market access
22 Appendix
23 DelveInsight Capabilities
24 Disclaimer
25 About DelveInsight<\/p>\n

View report: https:\/\/www.delveinsight.com\/report-store\/acute-respiratory-distress-syndrome-ards-market<\/span><\/a><\/strong><\/p>\n

About DelveInsight<\/strong>
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.<\/strong><\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight Business Research LLP<\/a>
Contact Person:<\/strong> Kritika Rehani
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 9193216187
Address:<\/strong>304 S. Jones Blvd #2432
City:<\/strong> Las Vegas
State:<\/strong> Nevada
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

DelveInsight Business Research LLP DelveInsight\u2019s \u2018Acute Respiratory Distress Syndrome (ARDS) – Market Insights, Epidemiology and Market Forecast – 2030\u2019 report delivers an in-depth understanding of the Acute Respiratory Distress Syndrome (ARDS), historical and forecasted epidemiology as well as the Acute … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-533345","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/533345","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=533345"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/533345\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=533345"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=533345"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=533345"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}